iFSP1
Based on 32 publication(s) in Google Scholar
iFSP1 is a potent, selective and glutathione-independent inhibitor of ferroptosis suppressor protein 1 (FSP1) (AIFM2) with an EC50 of 103 nM. iFSP1 selectively induces ferroptosis in GPX4-knockout cells which overexpressed FSP1. iFSP1 is able to sensitize a variety of human cancer cell lines to the ferroptosis inducer, such as (1S,3R)-RSL3 (HY-100218A).
For research use only. We do not sell to patients.
- Purity: 99.96%
- CAS No.: 150651-39-1
- Formula: C20H13N5
- Molecular Weight:323.35
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) iFSP1
More- Nature. 2026 Jan;649(8096):477-486. [Abstract]
- Nat Cancer. 2025 May;6(5):768-785. [Abstract]
- Adv Mater. 2023 Apr;35(14):e2211579. [Abstract]
- Nat Commun. 2024 Sep 1;15(1):7611. [Abstract]
- Nat Commun. 2023 Oct 30;14(1):6908. [Abstract]
- Autophagy. 2026 Feb 15:1-19. [Abstract]
- Adv Sci (Weinh). 2025 Dec;12(46):e04245. [Abstract]
- Sci Adv. 2026 May 29;12(22):eaeb2368. [Abstract]
- Cell Discov. 2022 May 3;8(1):40. [Abstract]
- Small. 2021 Aug;17(32):e2101368. [Abstract]
- Cell Rep Med. 2025 Jan 27:101928. [Abstract]
- Cell Death Dis. 2025 Apr 6;16(1):257. [Abstract]
- Cell Death Dis. 2023 Aug 26;14(8):567. [Abstract]
- Adv Healthc Mater. 2023 Oct;12(27):e2300994. [Abstract]
- Cell Death Dis. 2022 May 18;13(5):468. [Abstract]
- Cell Death Dis. 2022 Jan 21;13(1):73. [Abstract]
- Genes Dis. 2023 Jan 3;11(1):449-463. [Abstract]
- Free Radic Biol Med. 2025 Aug 11:240:238-252. [Abstract]
- Br J Pharmacol. 2024 Oct;181(20):4067-4084. [Abstract]
- Transl Res. 2024 May 24:S1931-5244(24)00107-5. [Abstract]
- Chem Biol Interact. 2024 Dec 1:404:111262. [Abstract]
- Am J Respir Cell Mol Biol. 2025 May;72(5):551-562. [Abstract]
- J Nutr Biochem. 2025 Jun:140:109886. [Abstract]
- Int Immunopharmacol. 2026 Jan 1;168(Pt 2):115892. [Abstract]
- Mol Neurobiol. 2024 May 11. [Abstract]
- J Biol Chem. 2026 May 27;302(7):113200. [Abstract]
- Sci Rep. 2025 Jan 12;15(1):1754. [Abstract]
- J Biol Chem. 2024 Sep;300(9):107678. [Abstract]
- Mol Carcinog. 2025 Jul 17. [Abstract]
- bioRxiv. 2026 May 23:2026.05.20.726695. [Abstract]
- Queen Mary University of London. 2025.
- Research Square Preprint. 2023 May 17.
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
-
WB
Biological Activity
|
FSP1 |
iFSP1 (0.001-1 μM; 24 hours) inhibits the Gpx4-knockout cell growth as a dose-dependent manner, but does not inhibit the wild type cell growth. Treatment with the ferroptosis inhibitor Lip-1 protects GPX4- knockout cells from iFSP1-induced ferroptosis[1].iFSP1 (0.001-1 μM; 24 hours) is less efficient than genetic deletion of FSP1, whereas iFSP1 treatment in the FSP1-knockout background had no additive effect to RSL3-induced ferroptosis[1].iFSP1 (3 μM; 24 hours) treatment results in an obvious toxicity of RSL3 in a panel of genetically engineered (FSP1-knockout) human cancer cell lines[1].AIFM2: the flavoprotein apoptosis-inducing factor mitochondria-associated 2 is a previously unrecognized anti-ferroptotic gene. AIFM2, which is renamed ferroptosis suppressor protein 1 (FSP1)[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Wild-type and Gpx4-knockout Pfa1 or HT 1080 cells overexpressing FSP1–HA
-
Concentration:0.001-1 μM
-
Incubation Time:24 hours
-
Result:Was toxic to cells that depend solely (no GPX4 expression detectable) on FSP1 function.
-
Cell Line:NCl-H1437, NCl-H1437 FSP1 KO, U-373, U-373 FSP1 KO, MDA-MB-436, MDA-MB-436 FSP1 KO, SW620, SW620 FSP1 KO, MDA-MB-435S, MDA-MB-435S FSP1 KO, A549 and A549 FSP1 KO
-
Concentration:3 μM
-
Incubation Time:24 hours
-
Result:Sensitized a variety of human cancer cell lines to the ferroptosis inducer (1S,3R)-RSL3.
Chemical Information
-
CAS No. 150651-39-1
-
Appearance Solid
-
Molecular Weight 323.35
-
Formula C20H13N5
-
Color Light yellow to yellow
-
SMILES
N#CC1=C(N)N2C3=CC=CC=C3N=C2C(C#N)=C1C4=CC=C(C)C=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (32)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 Jan;649(8096):477-486. PMID: 41193799
iFSP1 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Jan;649(8096):477-486. [Abstract]
Cell viability of A-375 cells ± iFSP1 (10 μM) ± BSO (1 mM) or combinations for 48 h.
-
Nat Cancer
Palmitoylation of GPX4 via the targetable ZDHHC8 determines ferroptosis sensitivity and antitumor immunity. [Abstract]2025 May;6(5):768-785. PMID: 40108413 -
Adv Mater
2023 Apr;35(14):e2211579. PMID: 36637436 -
Nat Commun
Suppression of ferroptosis by vitamin A or radical-trapping antioxidants is essential for neuronal development. [Abstract]2024 Sep 1;15(1):7611. PMID: 39218970 -
Nat Commun
Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis. [Abstract]2023 Oct 30;14(1):6908. PMID: 37903763
iFSP1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Oct 30;14(1):6908. [Abstract]
Ferroptosis inhibition by FXR activation is reverted when FSP1 or PPARα are inhibited. Ferroptosis was induced by 200 nM RSL3 for 18 h, 12 µM Turofexorate was used to inhibit ferroptosis. FSP1 was inhibited by iFSP1 (0.2, 1.5, 6.3, 25 μM), PPARα was inhibited by GW6471 (PPARαi).
-
Autophagy
Kitasamycin overcomes ferroptosis and immunotherapy resistance by targeting the HUWE1-NCOA4-FTH1 axis. [Abstract]2026 Feb 15:1-19. PMID: 41612599 -
Adv Sci (Weinh)
Trained Immunity Exacerbates Inflammatory Arthritis Progression via Promoting Synovial Fibroblast Ferroptotic Resistance. [Abstract]2025 Dec;12(46):e04245. PMID: 41255239
iFSP1 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Dec;12(46):e04245. [Abstract]
Schematic representation of the experimental induction of trained immunity in CIA treated with iFSP1 (10.0 mg kg−1 daily), Arthritis index and paw thickness were scored and compared with CIA. the establishment of a trained immunity model (β‐glucan or PBS) was initiated on day 0, the establishment of a CIA rat model was initiated on day 7, CIA was re‐enforced on day 14, and ferroptosis induction was initiated by daily intraperitoneal injection of iFSP1 (10.0 mg/kg/ daily) on day 14, the experiment was terminated on day 35.
iFSP1 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Dec;12(46):e04245. [Abstract]
Representative photographs of morphology in different groups, H&E, toluidine blue O, and safranin O staining of representative joints in different groups. the establishment of a trained immunity model (β‐glucan or PBS) was initiated on day 0, the establishment of a CIA rat model was initiated on day 7, CIA was re‐enforced on day 14, and ferroptosis induction was initiated by daily intraperitoneal injection of iFSP1 (10.0 mg/kg/ daily) on day 14, the experiment was terminated on day 35.
-
Sci Adv
2026 May 29;12(22):eaeb2368. PMID: 42213853 -
Cell Discov
Dynamic O-GlcNAcylation coordinates ferritinophagy and mitophagy to activate ferroptosis. [Abstract]2022 May 3;8(1):40. PMID: 35504898
iFSP1 purchased from MedChemExpress. Usage Cited in: Cell Discov. 2022 May 3;8(1):40. [Abstract]
U2OS cells were treated with iFSP1 (10 µM; 0, 0.5, 1, 2, 4, 8 h). O-GlcNAcylation levels were detected by immunoblotting with antibodies against O-GlcNAc and β-actin, and the relative intensity (O-GlcNAc/b-actin) was quantified.
-
Small
A Ferrocene-Functionalized Covalent Organic Framework for Enhancing Chemodynamic Therapy via Redox Dyshomeostasis. [Abstract]2021 Aug;17(32):e2101368. PMID: 34216420 -
Cell Rep Med
Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis. [Abstract]2025 Jan 27:101928. PMID: 39879992 -
Cell Death Dis
Pharmacological targeting of the mitochondrial phosphatase PTPMT1 sensitizes hepatocellular carcinoma to ferroptosis. [Abstract]2025 Apr 6;16(1):257. PMID: 40189563 -
Cell Death Dis
FSP1 confers ferroptosis resistance in KEAP1 mutant non-small cell lung carcinoma in NRF2-dependent and -independent manner. [Abstract]2023 Aug 26;14(8):567. PMID: 37633973 -
Adv Healthc Mater
2023 Oct;12(27):e2300994. PMID: 37432874 -
Cell Death Dis
Involvement of FSP1-CoQ10-NADH and GSH-GPx-4 pathways in retinal pigment epithelium ferroptosis. [Abstract]2022 May 18;13(5):468. PMID: 35585057 -
Cell Death Dis
RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m6A-dependent manner. [Abstract]2022 Jan 21;13(1):73. PMID: 35064112 -
Genes Dis
CD36 promotes tubular ferroptosis by regulating the ubiquitination of FSP1 in acute kidney injury. [Abstract]2023 Jan 3;11(1):449-463. PMID: 37588197 -
Free Radic Biol Med
Baicalein attenuates metabolic dysfunction-associated steatohepatitis by regulating macrophage ferroptosis through nuclear factor (erythroid-derived 2)-like 2 pathway. [Abstract]2025 Aug 11:240:238-252. PMID: 40803417 -
Br J Pharmacol
IDH2-NADPH pathway protects against acute pancreatitis via suppressing acinar cell ferroptosis. [Abstract]2024 Oct;181(20):4067-4084. PMID: 39072736 -
Transl Res
2024 May 24:S1931-5244(24)00107-5. PMID: 38797432 -
Chem Biol Interact
4-Hydroxybenzoic acid restrains Nlrp3 inflammasome priming and activation via disrupting PU.1 DNA binding activity and direct antioxidation. [Abstract]2024 Dec 1:404:111262. PMID: 39389441 -
Am J Respir Cell Mol Biol
2025 May;72(5):551-562. PMID: 39453438 -
J Nutr Biochem
Diosgenin alleviates lipid accumulation in NAFLD through the pathways of ferroptosis defensive and executive system. [Abstract]2025 Jun:140:109886. PMID: 40023201 -
Int Immunopharmacol
2026 Jan 1;168(Pt 2):115892. PMID: 41273847 -
Mol Neurobiol
Edaravone Alleviates Traumatic Brain Injury by Inhibition of Ferroptosis via FSP1 Pathway. [Abstract]2024 May 11. PMID: 38733490 -
J Biol Chem
The iron-sulfur cluster assembly factor FDX2 is required for tumor initiation but not for growth of established tumors in transplantation models. [Abstract]2026 May 27;302(7):113200. PMID: 42208897 -
Sci Rep
Exploring Liraglutide's mechanism in reducing renal fibrosis: the Fsp1-CoQ10-NAD(P)H pathway. [Abstract]2025 Jan 12;15(1):1754. PMID: 39799153 -
J Biol Chem
FDX2, an iron-sulfur cluster assembly factor, is essential to prevent cellular senescence, apoptosis or ferroptosis of ovarian cancer cells. [Abstract]2024 Sep;300(9):107678. PMID: 39151727 -
Mol Carcinog
Pregnane X Receptor Activation Induces Ferroptosis Resistance Through Upregulation of FSP1. [Abstract]2025 Jul 17. PMID: 40674609 -
bioRxiv
Ferrous Iron Accumulation Is a Hallmark and Therapeutic Vulnerability of Therapy-Induced Senescence. [Abstract]2026 May 23:2026.05.20.726695. PMID: 42239384 -
-
Solvent & Solubility
DMSO : 11.67 mg/mL (36.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2 mg/mL (6.19 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0926 mL | 15.4631 mL | 30.9262 mL | 77.3156 mL |
| 5 mM | 0.6185 mL | 3.0926 mL | 6.1852 mL | 15.4631 mL | |
| 10 mM | 0.3093 mL | 1.5463 mL | 3.0926 mL | 7.7316 mL | |
| 15 mM | 0.2062 mL | 1.0309 mL | 2.0617 mL | 5.1544 mL | |
| 20 mM | 0.1546 mL | 0.7732 mL | 1.5463 mL | 3.8658 mL | |
| 25 mM | 0.1237 mL | 0.6185 mL | 1.2370 mL | 3.0926 mL | |
| 30 mM | 0.1031 mL | 0.5154 mL | 1.0309 mL | 2.5772 mL |